Evidence map›Paper›PMID 19290518›Full record

ArticleEuropean biophysics journal : EBJ2010

Recombinantly produced hydrophobins from fungal analogues as highly surface-active performance proteins.

Wendel Wohlleben, Thomas Subkowski, Claus Bollschweiler, Bernhard von Vacano, Yaqian Liu, Wolfgang Schrepp, Ulf Baus

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wendel WohllebenPolymer Physics Research, BASF SE, 67056 Ludwigshafen, Germany. wendel.wohlleben@basf.com
Thomas Subkowski
Claus Bollschweiler
Bernhard von Vacano
Yaqian Liu
Wolfgang Schrepp
Ulf Baus

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrophobins are available from natural resources only in milligram amounts. BASF succeeded in a recombinant production process, up-scaled to pilot plant production in kilogram scale. Strain and protein optimization by modulation of gene expression and generation of fusion proteins finally leads to two class I hydrophobins called H*Protein A and H*Protein B. By analytical ultracentrifugation, we confirm that the self-association of H*Proteins in solution is governed by their sequence, because oligomerization is induced by the same mechanisms (pH > 6, temperature >> 5 degrees C, concentration > 0.2 mg/ml) as for the well-known native hydrophobins SC3 and HFB II. Additionally, we established the triggering of structure formation by bridging with divalent ions and the stabilization of dimers and tetramers by monovalent ions or surfactants. This interplay with surfactants can be exploited synergistically: The capacity for emulsification of a 300 ppm standard surfactant solution is boosted from 0 to 100% by the addition of a mere 1 ppm of our new hydrophobins, with H*Protein A and H*Protein B having specific application profiles. This astonishing performance is rationalized by the finding that the same minute admixtures enhance significantly the interfacial elastic modulus, thus stabilizing interfaces against coalescence and phase separation.

Indexed as

Aspergillus nidulansBacillus subtilisBacterial ProteinsCalciumCations, DivalentCloning, MolecularElasticityEscherichia coliFungal ProteinsHydrogen-Ion ConcentrationHydrophobic and Hydrophilic InteractionsKineticsProtein MultimerizationRecombinant Fusion ProteinsSodiumSolutionsBacterial ProteinsCalciumCations, DivalentDEWA protein, Asperigillus nidulansFungal ProteinsRecombinant Fusion ProteinsSodiumSolutionsSurface-Active Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.